{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:59Z","timestamp":1793896019400,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["project 22,377,011"],"award-info":[{"award-number":["project 22,377,011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110247","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:01:59Z","timestamp":1783983719000},"page":"110247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"180","author":[{"given":"Heng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110247_bb0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaoncol.2024.1930","article-title":"Pancreatic cancer surveillance and survival of high-risk individuals","volume":"10","author":"Blackford","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113471","article-title":"Risk factors for early-onset pancreatic ductal adenocarcinoma: a systematic literature review","volume":"198","author":"Chandana","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110247_bb0015","article-title":"Advances in pancreatic cancer early diagnosis, prevention, and treatment: the past, the present, and the future","volume":"76","author":"Mannucci","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110247_bb0020","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0030","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jjco\/hyaf012","article-title":"Current status of cancer genome medicine for pancreatic ductal adenocarcinoma","volume":"55","author":"Doi","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17425255.2019.1620731","article-title":"Pharmacogenetics of treatments for pancreatic cancer","volume":"15","author":"El Hassouni","year":"2019","journal-title":"Expert Opin Drug Met."},{"key":"10.1016\/j.bioorg.2026.110247_bb0045","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110247_bb0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41392-024-02031-8","article-title":"Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib\/II trial","volume":"9","author":"Cheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110247_bb0055","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.3390\/curroncol30110694","article-title":"A simple overview of pancreatic cancer treatment for clinical oncologists","volume":"30","author":"Garajov\u00e1","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101803","article-title":"Pancreatic ductal adenocarcinoma: emerging therapeutic strategies","volume":"43","author":"Osei-Bordom","year":"2022","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/13543784.2025.2473698","article-title":"Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years","volume":"34","author":"Mosalem","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.110247_bb0070","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1021\/acs.jmedchem.4c03006","article-title":"Concept of targeted drug conjugate and its application in reversing drug resistance","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110247_bb0075","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acs.inorgchem.6c00964","article-title":"Application of PARP1-specific Pt(II)-based targeted drug conjugate in the treatment of ovarian cancer by inhibiting PARP1 and suppressing DNA damage repair","volume":"65","author":"Xu","year":"2026","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110247_bb0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","article-title":"EGFR-activated myofibroblasts promote metastasis of pancreatic cancer","volume":"42","author":"Mucciolo","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110247_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101070","article-title":"A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR","volume":"59","author":"Han","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.bioorg.2026.110247_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12029-024-01149-w","article-title":"Advances in novel targeted therapies for pancreatic adenocarcinoma","volume":"56","author":"Hoang","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.bioorg.2026.110247_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110247_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2021.03.022","article-title":"Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer","volume":"508","author":"Lin","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110247_bb0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41420-026-03040-y","article-title":"SNHG10 promotes tumorigenesis through the EGFR\/AKT\/ERK\/mTOR and miR-150-5p\/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma","volume":"12","author":"Pandya","year":"2026","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bioorg.2026.110247_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114304","article-title":"Topoisomerase I inhibitors: challenges, progress and the road ahead","volume":"236","author":"Talukdar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110247_bb0115","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cbic.202000752","article-title":"Application of DNA-alkylating pyrrole-imidazole polyamides for cancer treatment","volume":"22","author":"Maeda","year":"2021","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bioorg.2026.110247_bb0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-024-01948-4","article-title":"Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial","volume":"9","author":"Cui","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110247_bb0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/j.gastro.2025.02.038","article-title":"Therapeutic targeting of oncogene-induced transcription-replication conflicts in pancreatic ductal adenocarcinoma","volume":"169","author":"Smith","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2026.110247_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112190","article-title":"Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance","volume":"193","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110247_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2025.113165","article-title":"Potent anticancer 5-fluorouracil platinum(IV) prodrugs","volume":"276","author":"Khoury","year":"2026","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bioorg.2026.110247_bb0140","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1021\/nn300149c","article-title":"Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates","volume":"6","author":"Tang","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioorg.2026.110247_bb0145","article-title":"Synthesis and anticancer evaluation of PCNA inhibitor AOH1996 analogs in cancer cell cultures","volume":"31","author":"Jonu\u0161ein\u0117","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110247_bb0150","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s12094-023-03106-8","article-title":"New thoughts and findings on invasion and metastasis of pancreatic ductal adenocarcinoma (PDAC) from comparative proteomics: multi-target therapy","volume":"25","author":"Liu","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0155","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/ijms21103534","article-title":"SMAD4 and the TGF\u03b2 pathway in patients with pancreatic ductal adenocarcinoma","volume":"21","author":"Dardare","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110247_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1442737","article-title":"Sulforaphane regulates cell proliferation and induces apoptotic cell death mediated by ROS-cell cycle arrest in pancreatic cancer cells","volume":"14","author":"Cho","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.745554","article-title":"PPAR\u03b3\/SOD2 protects against mitochondrial ROS-dependent apoptosis via inhibiting ATG4D-mediated mitophagy to promote pancreatic cancer proliferation","volume":"9","author":"Nie","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.110247_bb0170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41389-025-00591-0","article-title":"Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer","volume":"14","author":"Abdel Hadi","year":"2025","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bioorg.2026.110247_bb0175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10555-021-09983-1","article-title":"Targeting DNA damage repair pathways in pancreas cancer","volume":"40","author":"Crowley","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bioorg.2026.110247_bb0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jcp.30573","article-title":"Molecular mechanisms involved in DNA repair in human cancers: an overview of PI3k\/Akt signaling and PIKKs crosstalk","volume":"237","author":"Alemi","year":"2022","journal-title":"J. Cell. Physiol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:56:35Z","timestamp":1793894195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S0045206826007832"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110247","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110247"}}